Supernus Set To Launch Trokendi XR Against Generic Topamax
This article was originally published in The Pink Sheet Daily
The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.
You may also be interested in...
At least two companies in the neuroscience space are set to deliver potentially good news by year’s end, with other promising candidates in the offing, according to industry consultant Harry Tracy, who compiled a list of the top 10 partnering opportunities in the field for the upcoming Therapeutic Area Partnerships meeting.
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.